Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China · Delayed Price · Currency is CNY 31.74
-0.41 (-1.28%)
Mar 30, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Revenue
In the year 2025, Hangzhou Biotest Biotech had annual revenue of 448.37M CNY, down -19.85%. Hangzhou Biotest Biotech had revenue of 140.30M in the quarter ending December 31, 2025, a decrease of -17.77%.
Revenue
448.37M
Revenue Growth
-19.85%
P/S Ratio
10.36
Revenue / Employee
743.57K
Employees
622
Market Cap
4.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 448.37M | -111.03M | -19.85% |
| Dec 31, 2024 | 559.40M | 117.29M | 26.53% |
| Dec 31, 2023 | 442.11M | -1.46B | -76.75% |
| Dec 31, 2022 | 1.90B | 83.07M | 4.57% |
| Dec 31, 2021 | 1.82B | 952.70M | 110.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Wuhan Hvsen Biotechnology | 1.67B |
| Hefei Lifeon Pharmaceutical | 1.47B |
| Pulike Biological Engineering | 1.10B |
| ChemPartner PharmaTech | 1.07B |
| Beijing Bohui Innovation Biotechnology Group | 834.38M |
| PharmaResources (Shanghai) | 667.47M |
| Assure Tech (Hangzhou) | 453.58M |
| Innovita Biological Technology | 422.03M |